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During the past decade, this country has wit-
nessed an increased emphasis on pain manage-
ment and palliative care. Clinicians are being
encouraged to more effectively alleviate pain in
terminally ill patients, and there has been an inten-
sified effort to encourage individuals to establish
advance directives such as resuscitation status,
living wills, and power of attorney. The routine
assessment of pain has been advanced as the
"fifth vital sign." These and other initiatives have
raised awareness about end-of-life issues, and
have contributed to an evolving standard of care
for terminally ill patients.
Meanwhile, determinate sentencing, "three
strikes" laws, and anti-drug initiatives have led to
an overwhelming increase in the number of pris-
oners in this country. As of June 2002, 2.1 million
people were incarcerated in this country's jails and
prisons - the first time the U.S. prison and jail pop-
ulation exceeded two million.1 At the same time,
the prison population is aging, with an increase in
the proportion of inmates over 50 years old.
Prisoners have a higher prevalence of HIV infec-
tion, hepatitis C infection, tobacco addiction, alco-
holism, substance abuse, chronic lung diseases,
and musculoskeletal disorders than similarly aged
men and women who are not incarcerated.2 Many
inmates received inadequate health care prior to
incarceration, and therefore present with more
sequelae and more advanced forms of their
chronic illnesses.
In spite of this increase in the number of aging,
chronically and terminally ill inmates, most people
give little thought to how prisoners die. However,
case law has established a constitutional duty
under the 8th Amendment to provide care to the
incarcerated that is not "indifferent to serious med-
ical needs."3 Certainly, the alleviation of pain and
suffering of the terminally ill falls under this
requirement. 
Recently, several groups have brought attention to
palliative care in the correctional setting.
Standards have been drafted to help guide those
providing palliative and hospice care to prison-
ers.4,5,6 As of 2001, formal correctional end-of-life
care programs were in place in 33 states and the
Federal Bureau of Prisons, with more programs
under development.4 The World Health
Organization has published two booklets detailing
pain and symptom management.7,8 What follows
is based upon these publications (see related
resources on page 5) and the author's experi-
ences caring for terminally ill inmates.
Pain and Symptom Management
Terminally ill patients frequently experience pain
and other unpleasant symptoms secondary to
their underlying illness. Each patient should
undergo a careful initial evaluation of his or her
pain. A pain history should include pain location,
severity, aggravating and alleviating factors,
whether the pain is constant or intermittent, if the
pain interferes with daily activities or sleep, and
what treatments have and have not worked in the
past. 
Patients should undergo a careful initial physical
exam, which should be repeated regularly during
the course of the patient's illness. Radiographic
studies can detect bone lesions that might be
treated with palliative radiotherapy. In general,
studies should be limited to those that are intend-
ed to lead to relief of pain or other unpleasant
symptoms.
Anger, anxiety, and depression are common in
those who are terminally ill. A careful psychologi-
cal evaluation is therefore important when con-
structing a comprehensive treatment plan for the
patient. The involvement of mental health profes-
sionals who are experienced with death and dying
issues is invaluable.  
Nociceptive and Neuropathic
Pain
Pain can be classified as either nociceptive or
neuropathic, and each type responds differently to
treatment. Nociceptive pain occurs when nerve
endings are stimulated, such as when a tumor
expands in an organ, or metastasizes to bone.
Neuropathic pain occurs when a nerve is injured
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or compressed, and can involve peripheral or
central nerves.
Nociceptive pain is usually responsive to
analgesics, whereas neuropathic pain may
not be adequately relieved by analgesics
alone. With neuropathic pain, additional
benefit may be achieved with the use of tri-
cyclic antidepressants or anticonvulsants.
Amitriptyline or imipramine in starting doses
of 25-50 mg orally each day can provide sig-
nificant relief. Doses should be titrated as tol-
erated to 50-100 mg each day. These agents
should be administered at bedtime as they
can cause sedation, dry mouth, and postural
hypotension. The anticonvulsants carba-
mazepine (Tegretol) and valproic acid
(Depakene) can also be helpful in the treat-
ment of neuropathic pain. Carbamazepine
should be started at an initial dose of 100 mg
twice daily and increased by 200 mg a day
every few days as tolerated. Valproic acid is
initially dosed at 500 mg at bedtime, and
increased if necessary 200 mg every few
days to a maximum dose of 1500 mg. 
Administering Analgesics
The World Health Organization emphasizes
that analgesics should be given by mouth and
on a fixed schedule. In situations where oral
treatment is not feasible, rectal suppositories,
transdermal patches, or subcutaneous injec-
tions can be used. (See Tables 1 and 2 for
dosing schedules of common analgesics.)
Analgesics prescribed for severe pain in the
setting of a terminal illness should be admin-
istered at fixed intervals to avoid cycles of
poorly controlled pain and the associated
anxiety and psychological distress of worrying
about the next dose of medication. Analgesic
doses should be increased as needed, with
each subsequent dose administered before
the prior dose has worn off. If the patient waits
until the pain is significant before requesting
an additional dose, consistent relief of pain
will not be achieved. Long-acting analgesics
should be used for the majority of a patient's
daily dose, with additional rescue doses pre-
scribed for "breakthrough" pain caused by
activities such as movement or dressing
changes. Typical rescue doses should be 50-
100% of the dose being given every 4 four
hours.
With regular use, tolerance to narcotic anal-
gesics commonly develops. This physiologic
process necessitates the use of higher nar-
cotic doses to provide the same degree of
relief. Patients develop a physical depen-
dence and will experience withdrawal symp-
toms if narcotics are rapidly tapered or dis-
continued. This is not the same as addiction
or psychological dependence, where patients
demonstrate cravings for narcotics and a pre-
occupation with getting them.
Most pain can be relieved with appropriate
doses of analgesics. When treating pain in
terminally ill patients, the right dose is the
dose that provides adequate pain relief.
Depending on the patient, this could be 5 mg
to 1000 mg of morphine (or its equivalent)
every four hours. It may also be necessary to
decrease the dosing interval of extended-
release oral transdermal preparations.
Since most narcotics are metabolized by the
liver, caution is necessary when treating
patients with serious liver disease. Most nar-
cotics are excreted by the kidneys, so individ-
uals with renal failure can have metabolite
accumulation. Dosing should be individual-
ized based upon pain relief and side effects.
Mitigating Analgesic Side
Effects
Common side effects of narcotic analgesics
include constipation, nausea, and emesis.
Drowsiness and confusion often occur when
narcotic analgesics are first taken. With time,
these side effects tend to diminish. Patients
who continue to be sedated or confused may
require a dose reduction.
Laxatives should be prescribed for all patients
receiving narcotics before problems with con-
stipation develop. The routine use of a stool
softener, such as docusate 200 mg, 2-3 times
a day is useful. The additional regular use of
n oral agent that stimulates peristalsis (such
as senna) is often sufficient to maintain regu-
lar bowel function. The dose of senna is 2
tablets every 6-12 hours. Patients will also
occasionally require a stimulant laxative sup-
pository or an enema to relieve more severe
constipation.
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Medication 
Aspirin 
Acetaminophen (Tylenol)
Ibuprofen (Motrin)
Indomethacin (Indocin)
Tramadol* (Ultram)
Dose
500 mg 
650 mg 
400-600 mg 
25 mg 
50-100 mg
Interval
Every 4-6 hours
Every 4-6 hours, max 3 grams/day
Every 4-6 hours
Every 6 hours
Every 4-6 hours
Table 1: Non-Narcotic Oral Analgesics 
* Tramadol is a centrally acting synthetic analgesic with both narcotic and non-narcotic properties.
Table 2: Narcotic Analgesics** 
Medication
Codeine
Morphine
Oxycodone 
(Roxicodone,
OxyContin)
Levorphanol
(Levo-Dromoran)
Methadone
Fentanyl 
(Duragesic)
Dose
Starting 
Dose 30 mg
10-15 mg
5-15 mg
1-2 mg
5-10 mg
50-75 mg 
Route
By mouth
By mouth, rectum,
or subcutaneous 
injection 
By mouth or 
rectum
By mouth
By mouth
Transdermal patch
Dosing Interval
Every 4 hours
Every 4 hours (long-acting tablets
are dosed every 12 hours)
Every 4-6 hours (long-acting
tablets are dosed every 12 hours)
Every 6 hours
Every 6-12 hours
Replace patch every 72 hours
**Complete prescribing information is beyond the scope of this article. Clinicians should consult a
more complete reference prior to prescribing for patients.
Table 3: Medications for the Treatment of Nausea and Vomiting
Drug class
Neuroleptics
Antihistamines
Prokinetics
Medication
Prochlorperazine (Compazine) 
Prochlorperazine  (Compazine)
suppository
Promethazine hydrochloride
(Phenergan)
Hydroxyzine (Atarax, Vistaril)
Metoclopramide (Reglan)
Dose     
5-10 mg 
every 6-8 hours
25 mg 
every 12 hours
25 mg every 4-6
hours as needed
50-100 mg 
every 6-8 hours
10-20 mg 
every 6 hours
Preferred route
By mouth
By rectum
By mouth or 
rectum
By mouth
By mouth
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Dear Colleagues:
This month we have two substantive articles vital to all correctional providers. Dr. Joseph Bick
gives a practical, erudite explication of providing palliative and end-of-life care in correctional
facilities.  Likewise, Dr. Stephen Tabet presents a case study of a patient with AIDS and wide-
ly metastatic lung cancer who has decided he does not want chemotherapy but is concerned
about pain. Dr. J. Randall Curtis of the University of Washington provides the case study dis-
cussion, noting issues the physician should address first, what issues to address with the
patient and how, and other important aspects of the case to consider. 
This clinical approach is juxtaposed with a very real example of an inmate's personal experi-
ence: a letter recently received at the California Medical Facility from the wife of an inmate who
died in the prison hospice, and who kindly allowed us to publish her letter in this issue.
All correctional providers have to deal with death and dying. This issue of HEPP Report once
again provides front-line correctional clinicians the tools needed to approach the problem, as
well as the thought processes needed to approach the problem well. These articles recognize
the need to involve the entire correctional system in providing the residents with quality end-
of-life care. Specific suggestions to involve correctional administration and staff on this issue
are invaluable. Death and dying is something most people can empathize with, and this aspect
of care can serve as a bridge for other areas of health care interaction with security staff. 
After reading this month's issue, you should be familiar with the issues surrounding palliative
and end-of-life care to for inmates, including managing pain effectively, communicating with
patients, and overcoming challenges unique to the correctional system. As usual, every issue
of HEPP Report has tremendous value and provides CME credit as well. This one is no excep-
tion. Enjoy it and I hope you learn as much as I did. 
Sincerely,
David L. Thomas, M.D., J.D.
Chair, Division of Correctional Medicine and Department of Surgery
NSU-COM, Ft. Lauderdale, Fla. 
Letter from the Editor
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Nausea and vomiting are common in
patients being treated with narcotic anal-
gesics. These symptoms can also be due to
concomitant medications, constipation, renal
failure, gastrointestinal disease, electrolyte
abnormalities, and central nervous system
disease. An effort should be made to deter-
mine the etiology of the patient's symptoms.
Some useful medications for managing nau-
sea and vomiting are listed in Table 3.
Challenges in Correctional
Settings
Approximately 75% of prisoners have a his-
tory of drug and/or alcohol abuse.9 Given the
opportunity, many prisoners continue to
abuse drugs while incarcerated. Some pris-
oners who lack valid indications for narcotic
analgesics amplify their symptoms in an
attempt to obtain a prescription for these
medications. Other patients who have a
legitimate need for narcotics are victimized
by inmates who coerce them to give up
some or all of their medications. Correctional
staff who witness these behaviors may
actively discourage clinicians from prescrib-
ing these medications or create other road-
blocks, and clinicians who have been
deceived by prisoners may be less likely to
believe their patients. 
Solutions
Directly observed therapy (DOT) can be
used to limit the diversion of controlled sub-
stances. Except in the case of slow release
preparations, consideration should be given
to crushing narcotics and mixing them with
water before administration. 
It is useful to have a formulary that presents
a broad range of options for the treating clin-
ician. Long-acting patches and pills are very
helpful for treating pain in terminally ill
patients. Some patients will be troubled by
side effects from one type of narcotic anal-
gesic, but will do well on another. The more
options available to the clinician, the more
likely that the patient's pain and other symp-
toms will be adequately addressed.
A multidisciplinary pain management team is
very useful. Team members can include the
attending physician, mental health clinicians,
nurses, pharmacists, neurologists, pain
management specialists, and a chaplain.
Utilizing the collective knowledge and expe-
rience of different disciplines increases the
likelihood that the patient will receive the
best possible individualized approach to his
or her symptoms.
Palliative Care Settings
Some systems routinely transfer all inmates
to community hospitals when they are near-
ing death. In many cases, however, the con-
tinuation of aggressive care is futile and
leads to unnecessary pain and suffering. In
an outside hospital, prisoners are more like-
ly to be shackled because of security con-
cerns. Family visitation may be more restrict-
ed in community facilities, which can result in
the dying patient spending their last days or
weeks isolated from family members and
others close to them. For many terminally ill
inmates who are not granted compassionate
parole or release, allowing the patient to die
in the correctional setting can be more com-
passionate than a hospital transfer. 
Palliative and end-of-life care can be provid-
ed in a number of settings. Although it is not
necessary to build a new unit to serve as a
hospice, physical plant modifications may be
required. If possible, do not house patients
who have opted for palliative care together
with those receiving aggressive curative
measures. Clinicians often find it difficult to
switch from a curative approach to a pallia-
tive model as they move from patient to
patient. Patients who have elected comfort
care often find it distressing to be housed
with those who are being treated more
aggressively, and may be troubled with
doubt and regret about their decision. 
Staff Commitment
Nothing will succeed in the correctional set-
ting without the support and active participa-
tion of senior custody staff. Correctional
administrators must believe that a program
of palliative and end-of-life care can be
securely provided, is fiscally prudent, and will
not result in adverse media attention and/or
litigation. Some correctional administrators
are receptive to the idea of improving end-of-
life care based upon their own personal
experiences with illness and death. Unless
legitimate security and fiscal issues are
addressed, however, few will be willing to
support this type of program.
Costs
End-of-life care programs may require addi-
tional staffing. On the other hand, the costs
associated with housing terminally ill patients
in acute care hospitals during their last
weeks or months can be extraordinary. In
many cases, the costs associated with a
quality end-of-life care program can be offset
by avoiding unnecessary community hospi-
talizations.
Hospice Admission Criteria
Not all health care providers are familiar with
hospice and palliative care. Obtaining a truly
informed consent to forego aggressive mea-
sures can be difficult within the correctional
environment. Prior to hospice placement,
patients should undergo a careful evaluation
to ensure that they do in fact have a terminal
illness likely to lead to death within the next
six months. An effort should be made to
ensure that all possible curative and or life
extending measures have been considered
and discussed with each patient. Patients
Providing Palliative Care...
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Continued on page 5
This letter was received in April
of 2003 at the California Medical
Facility Hospice in Vacaville,
California, and reprinted with the
permission of the family.
Dear Chaplain: 
I am writing to thank you for your dili-
gence in helping my son and I visit John*
on April 4, 2003. Because of your assis-
tance, my son Stephen* was able to
meet his birth father for the first time. I¹m
not sure you realize what this meant to
my son, although I am certain that you
understand what it meant to John.
When I told my son that I had heard that
his birth father was terminally ill and in
prison, Stephen struggled with the idea
of meeting his father after 25 years. It
took him a few hours to decide that he
would like to meet him if he could. That's
where you came in. Without your assis-
tance, it could have taken many months
to get in, and then it would have been
too late. Due to your diligence, my son
and I were able to meet with John and
give him and Stephen a sense of clo-
sure. In addition, my son has learned
many valuable lessons that he will carry
with him throughout his life. He has
learned to be more forgiving and less
judgmental; and to look at every individ-
ual as a human being. He also learned
that John didn't abandon Stephen, John
abandoned himself. In the few hours that
we were there, Stephen's years of
hatred towards John dissolved into a
kind of loving understanding of his birth
father; not as a useless faceless crimi-
nal, but as a frail human being whose
mistakes cost him dearly. 
As of this writing, John passed away a
little more than 24 hours ago there at
CMF at the age of 48. I am hopeful that
his visit with the son he had not seen in
almost 25 years provided him some
measure of comfort and helped him tran-
sition into the world beyond this one,
even if he was not allowed the privilege
of dying a free man.
Once again, I want to thank you for your
efforts on our behalf and let you know
that you make a difference not only in
the lives of the inmates at CMF, but also
to those whose lives are connected to
those inmates. Please feel free to share
this letter with other staff and to let them
know that what they do is far more than
just a job. Thank you again. 
*All names have been changed.
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should be educated about hospice and palliative care, and given an
opportunity to visit the hospice unit. Assuming they choose to forego
curative measures, only then should the patients be consented for
transfer to the hospice unit.
Advanced Directives
Choosing hospice care is a decision to pursue comfort and palliation
over aggressive life-prolonging interventions. Patients should be given
the opportunity to decide whether they want to be resuscitated in the
event that their heart stops or they can no longer breathe without the
assistance of a ventilator. For most of those who elect hospice care, a
do not resuscitate (DNR) status is appropriate. However, requiring a
patient to choose DNR status in order to have access to hospice ser-
vices runs counter to community practice and can be coercive. 
Living wills, which provide guidelines for what a patient would like done
if he or she can no longer make medical decisions, can be useful.
Some patients prefer to designate a health care power of attorney.
Discussions should be held with patients as early as possible to ensure
that their preferences are respected. 
Volunteers
Both community and inmate volunteers can play an important role in a
correctional end-of-life program. Community volunteers can be recruit-
ed from local churches, mosques, synagogues, hospice organizations,
and religious-based service organizations. Many inmates are enthusi-
astic about participation in a pastoral care services (PCS) program,
and can improve terminally ill patients' quality of life. Some inmates
choose to participate as a way to seek personal redemption. Others,
facing the possibility of their own death in jail or prison, volunteer with
the hope that their participation will decrease the likelihood that they
will someday die alone.
All potential volunteers must be carefully screened prior to involvement
in a correctional PCS program. Volunteers from the community should
be interviewed to determine their motivation for involvement and
whether they appear to be suitable candidates. If deemed appropriate,
community volunteers must then undergo a custodial background
check to ensure that they have no criminal issues that would preclude
their involvement. Likewise, the PCS coordinator should carefully inter-
view inmates seeking to become volunteers. Potential inmate volun-
teers should be carefully evaluated by correctional staff to determine if
they have a history of preying on vulnerable individuals. Additional fac-
tors to consider include in-custody drug offenses and other recent rules
violations.
Education
An ongoing education program for caretakers of the terminally ill is
essential. Clinicians must be able to manage pain, nausea, emesis,
shortness of breath and other symptoms that occur in individuals with
terminal illnesses. All staff and volunteers should receive comprehen-
sive training before beginning work with terminally ill patients. Training
should cover basic concepts of death and dying, palliative and hospice
care, pain and symptom management, and the psychosocial aspects
of grief and loss. 
The orientation curriculum should be clear about what volunteers are
allowed to do for patients. Volunteers should not perform duties nor-
mally attended to by medical staff. For example, volunteers should not
medicate patients, bathe them, perform dressing changes, or obtain
vital signs. Volunteers should not have access to medical records, nor
should confidential details of patients' care be discussed with them.
Inmates are a particularly vulnerable class, especially when they are ill
and approaching death. The placement of  other prisoners in a position
where they could take advantage of dying inmates must be avoided.
For similar reasons, neither staff nor volunteers should be permitted to
eith r accept gifts from or be included in the wills of dying prisoners.
Visitation
Routine visitation policies rarely suffice when it comes to terminally ill
inmates. A system to facilitate visitation on short notice (at any time of
th  day or night) should be put into place. Additionally, rules pertaining
to minors and those with criminal histories may need to be modified if
dyi g prisoners are to have access to family members in their last
day . The clinical condition of patients can deteriorate suddenly.
Unless there is a close custody-medical interface, it is not likely that
such liberalized visitation policies for the terminally ill will succeed. If a
patient is close to death, he or she should be placed on a vigil status.
During vigil, a PCS worker should be allowed to remain at the patient's
bedside 24 hours a day, and family should have even greater access
to visitation. 
Family
For those who have been incarcerated for many years, "family" may
include other prisoners. If possible, an effort should be made to facili-
tate visits from inmates housed at the same facility if the patient con-
siders them family or close friends. 
For inmates who have lost contact with family but wish to communicate
with them, a mechanism should be in place to attempt to locate these
individuals. One option is to use an outside volunteer agency to help
locate family. Not all family members are willing to reestablish contact
with those who are incarcerated, or vice versa. In such cases, the
desire to maintain privacy should be respected. Even when family
members are willing to visit, there are frequently many unresolved
issues of anger and guilt. Family members may have been victims of
Providing Palliative Care... (continued from page 4)
End-of-Life Resources
National Prison Hospice Association
www.npha.org
npha@npha.org
Call: 303-544-5923
The GRACE Project
Guiding Responsive Action for Corrections at End-of-Life
www.graceprojects.org
graceprojects@voa.org
Call: 800-899-0089
World Health Organization
http://www.whocancerpain.wisc.edu/
American Academy of Hospice and Palliative Medicine
www.aahpm.org
Call: 847-375-6312
Centers to Improve Care of the Dying
www.medicaring.org
Call: 703-413-1100
Last Acts National Program Office
www.lastacts.org
Call: 202-338-9790
National Hospice and Palliative Care Organization
www.nhpco.org
Call: 703-243-5900
Standards for Health Services in Prisons
Published by the National Commission on Correctional Health
Care (NCCHC). Price: $59.95. Can be ordered online.
www.ncchc.org
Call: 773-880-1460
Continued on page 8
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Discussion: Although this patient has HIV infection, his cancer is what
limits his life expectancy. Patients with Stage IV lung cancer have a
median survival rate of less than four months. The inter-quartile range
on this estimate is relatively small, suggesting that this man is unlike-
ly to survive more than six months. 
What issues should the primary care provider deal with first?
The primary issues for this patient appear to be his possible depres-
sive symptoms and concern about pain management. The first issue I
will address is this patient's history of depression. It may be argued
that depression can adversely influence a person's treatment deci-
sions, and there is some evidence that depressed patients are more
likely to choose to forego life-sustaining treatments.1 However, just
because someone is depressed does not mean that he or she is not
competent to make treatment decisions. I would recommend that the
primary care clinician and psychiatrist assess this patient's competen-
cy to make decisions. If they deem him competent, his wishes should
be respected. Since his depression may respond to treatment, his
preferences for palliative care should be reassessed from time to time.
Data from the SUPPORT study suggest that when patients have a
decrease in depressive symptoms, they are more likely to accept life-
prolonging treatments.2
The second issue is the patient's concern about pain. Incarcerated
patients often become concerned about inadequate pain treatment,
especially since their complaints may be viewed with distrust by health
care providers. A recent study showed that pain is an important con-
cern among patients with HIV infection, particularly those with a histo-
ry of drug addiction.3 Pain is a common symptom among patients with
advanced AIDS4 and as many as two-thirds of these patients describe
moderate-to-severe or constant pain.5
Do you think consulting another oncologist is in order?
Chemotherapy for widely metastatic lung cancer is not curative and
the effect on duration of survival is minimal. However, recent advances
in chemotherapy and current regimens that are much less toxic than
they were several years ago make it a worthwhile option to consider.
After initiating palliative care and reassuring the patient that his pain
will be treated and that his treatment preferences will be respected, it
would be reasonable for the clinician to readdress the option of pallia-
tive chemotherapy and ask the patient if he is interested in discussing
this option with another oncologist.
When should end-of-life issues be discussed and how?
It is impossible to be prescriptive about the "right" time to discuss pal-
liative and end-of-life care. Often, clinicians wait until they have decid-
ed that life-sustaining treatments are no longer indicated before they
broach the subject of palliative and end-of-life care with patients or
their families. Studies suggest that clinicians are waiting for patients to
bring it up, while patients are waiting for clinicians to do so. In short,
raise the subject early, and revisit it on a regular basis.
Because discussing palliative care with patients is an important part of
providing high-quality care for patients with terminal illness, plan
a ead with the same care that you give to other medical procedures.
(1) Preparation: The clinician should review the patient's diagnoses,
v rious treatment options, and likely prognosis with each type of treat-
ment. It is important to know what has been communicated to the
patient by other members of the health care team. It is also important
to be familiar with the inmate's social support network, both in prison
and in his community; (2) Location: This discussion should take place
in a quiet and private room, safe from interruptions - admittedly difficult
in a correctional facility; (3) Participants: If possible, ask the patient
who should be present and what he or she would like to discuss; and
(4) Plan for what is likely to happen after the discussion. 
During these discussions, it is important to discuss prognosis and how
the illness will affect the patient in an honest and meaningful way. At
the same time, it is important to avoid completely discouraging hope
amo g patients or their significant others who want to remain hope-
ful.6,7
The discussion: First, review the treatment options and prognosis
honestly and directly. Spend some time exploring feelings and listen-
ing to the patient's reactions about the discussion. It can be helpful for
the clinician to repeat what the patient has said to show that the clini-
cian is listening. It also allows a chance for the patient to correct any
misunderstanding the clinician may have about what the patient said.
It is important to tolerate silences. Sometimes, after what seems like a
long silence, a patient will ask a particularly difficult question or
express a difficult emotion.
It is important that the clinician make recommendations during the dis-
cussion. With increasing emphasis on patient autonomy and surrogate
decision making, there may be a tendency for some clinicians to
describe treatment options to a patient or significant other and then
feel that they should not make a recommendation. On the contrary, it
is important that clinicians offer their expertise to patients and their sig-
nifi ant others, and part of this is offering sound recommendations. 
Concluding the discussion, the clinician should summarize the major
points and ask the patient if there are any questions. The clinician
should then propose an appropriate follow-up plan. This often includes
an appointment for a future meeting, and a way for the patient to get a
message to the clinician if questions arise before the next meeting.
There are a number of issues unique to the correctional environment
discussed in a recent publication from the HIV/AIDS Bureau of the
Health Services and Resources Administration.8 F r example, protect-
ing an inmate's medical confidentiality can be difficult. Corrections offi-
cers may be involved in discussions with medical staff about patient
care for security reasons. Also, the issue of advance directives is del-
icate in penal situations, where self-determination is, by definition,
abridged. Care providers must be assured that a patient's decisions
are voluntary regarding access to and withholding of life-sustaining
treatment.
Case presented by Stephen Tabet*, MD, MPH, Assistant Professor of Medicine, University of Washington, and Director, Northwest Correctional
Medicine Education Program, NW AIDS Education and Training Center. Discussion and recommendations by J. Randall Curtis*, MD, MPH, Associate
Professor of Medicine, Division of Pulmonary and Critical Care, University of Washington
A collaboration with the Northwest AIDS Education and Training Center, with Stephen Tabet, MD, and Kate Willner, trainer.
Ask the Expert
Case Study: End-of-life Care for Inmate with AIDS and Widely Metastatic Lung Cancer
(Continued on page 7)
Case: A 52 year-old African-American male inmate with Class B2 AIDS (CD4 cell count 421, HIV RNA 5,790) was diagnosed with widely
metastatic non-small cell carcinoma of the lung. He is currently taking multivitamins, citalopram (Celexa), and doxepin. He is being followed
for depression by the psychiatrist at the prison. The patient was seen by a community oncologist who explained treatment options and the
prognosis. The inmate decided that he does not want chemotherapy and wishes to be DNAR (Do Not Attempt Resuscitation). He is very con-
cerned about pain and wants to be assured that he will not suffer. The patient still has five years left of a six-year prison term and is unlikely
to get early release. The patient has been a devout Christian for the past year.
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Is there anything that would make end-of-life discussions differ-
ent given that the patient is African-American and a devout
Christian?
Culture and ethnicity are important factors to consider in patient-clini-
cian communication, especially when discussing palliative care. In
several studies of people with AIDS, black and Hispanic persons were
less likely to communicate with their primary care clinicians about end-
of-life care than Caucasian gay or bisexual men.9-11 People of color
with AIDS are more likely to report that they don't like to talk about end-
of-life care and are more likely to worry that talking about death could
bring death closer than are Caucasian patients with AIDS.12 Similarly,
injection drug users and women with high-risk sexual partners are
more likely to worry that talking about death it brings it closer.12
Caucasians are more likely to prefer a treatment approach that focus-
es on palliative care as opposed to extending life, and this association
persists even after controlling for education, income and HIV risk
behavior.13 While clinicians should be aware of the diversity of barriers
that may exist for patients from different cultures and be willing to dis-
cuss these barriers openly with patients,12,14 it is important to realize
that statistical associations by race and ethnicity are not predictive of
a particular individual's treatment preferences.
Some surveys suggest that many patients want to discuss spiritual or
religious issues with their primary care clinicians.15 Recent reviews
have suggested approaches that physicians can take in discussing
these matters with their patients.16,17A clinician can ask the patient if
there are aspects of his or her spirituality or religion that the patient
f els the clinician should know about in providing medical care. 
Is it possible to get a consult or assistance with end-of-life
issues?
Palliative medicine specialists can help clinicians and patients decide
on therapy goals and explain the available options for palliative treat-
ments, including potential palliative benefits of therapies frequently not
considered palliative, such as chemotherapy and antiretroviral thera-
py. Palliative medicine specialists help patients focus on what is most
important to them, helping them find value and meaning as their lives
come to a close. 
HRSA recently published A Clinical Guide for Supportive and Palliative
care Care for People with HIV/AIDS,8 available on the web at
http://hab.hrsa.gov. 
For information specific to customs of various ethnic and cultural
groups, see http://www.pallcare.asn.au/mc/mccontents.html.
Ask the Expert... (continued from page 6)
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Resources & Websites
"Hepatitis C: What Clinicians and Other Health Professionals
Need to Know"
www.cdc.gov/ncidod/diseases/hepatitis/c_training/edu/default.htm
A web-based training course for primary care physicians, nurses,
and other health care workers. Developed by the CDC's Division of
Viral Hepatitis and the Division of Media and Training Services. The
course can be completed in about 2 hours; ACCME, CNE, and
CEU continuing education credit is available.
New HIV Testing and Prevention Efforts
www.cdc.gov/mmwr/preview/mmwrhtml/
mm5215a1.htm
New CDC-issued policies for HIV testing and prevention. 
HIV Medication Chart
www.crine.org/info/pillchart.html
Drugs@FDA: A Catalog of FDA Approved Drug Products
www.accessdata.fda.gov/scripts/cder/drugcat/
A pilot project of the FDA that provides a single, searchable internet
source for official, up-to-date information about FDA-approved
brand name and generic drugs (including those for the treatment of
HIV/AIDS and related conditions). 
Interactive Database of Drug Interactions
hivinsite.ucsf.edu/InSite.jsp?page=ar-00-02
Drug Database
www.aidsinfo.nih.gov/drugs/fda_drug.asp
Searchable by drug name, class, or other search terms. Sponsored
by AIDSinfo, a service of the U.S. Department of Health and
Human Services.
Baltimore, Maryland, April 10, 2003  
By Joseph Paris*, M.D., Medical Director, Georgia Department of Corrections
Meeting Update: Society of Correctional
Physicians (SCP) 
The Society of Correctional Physicians (SCP) held its semiannual meeting in Baltimore,
Maryland, on April 10. The theme, Correctional Care of Infectious Diseases and Mental
Health Issues,  attracted experts willing to share recent developments with the audience
of correctional physicians. In the field of infectious disorders, contributions were given by
Drs. David Williamson of the C. T. Perkins Hospital Center,  David L. Thomas of Johns
Hopkins, Jay Hoofnagle of the National Institutes of Health, Glenn Treisman of Johns
Hopkins, and others.
Dr. Thomas emphasized the importance of HBeAg testing of all patients with chronic
hepatitis B virus (HBV). Patients with negative HBeAg tests and normal ALT levels are
"healthy carriers," he said. Indications for interferon treatment include persistently elevat-
ed ALT levels (over twice the normal level), abnormal liver histology, and absence of end-
stage liver disease. Sustained responders ("cures") will have no evidence of HBeAg, will
show corresponding antibodies (Anti-HBe), and ALT normalization. 
Dr. Hoofnagle described a new understanding of the natural history of chronic hepatitis C
(HCV) infection. In the absence of HIV coinfection, HCV may take up to 50 years to evolve
into fatal end-stage liver disease or hepatocellular carcinoma (HCC). HCV progression is
marked by development of liver fibrosis, as measured by Stages 1-4 liver histology.
Because therapies are constantly being improved, Hoofnagle stated that it might be pru-
dent to wait for better therapies for patients with early stages of fibrosis. Otherwise, he
said, a treatment failure may result and patients may not respond to retreatment with future
therapies. Dr. Hoofnagle also showed his recent compilation of end-of-follow-up "cure"
results for white and African American persons. Although the number of African American
patients treated was  small, a disturbing and unexplained lowered response rate was
noted. The significance of this difference is not yet known.
Dr. Williamson described common psychiatric complications of HIV disease. He distin-
guished patients who can be safely treated by primary care physicians from those who
may need psychiatric evaluation and follow-up. Lastly, Dr. Treisman reviewed mental
health approaches to patients with HIV infection and other conditions. He emphasized the
difficulty for psychiatrists to understand the motivations and social situation of the inmates
that they treat. These barriers may result in a relative inability to achieve substantial patient
rapport and therefore, less success in helping these patients.
Serologic testing for vaccinia is uninformative because it cannot be used to distinguish
vaccinia immunity from vaccinia infection unless baseline antibody titers are available. 
Diagnostic tests for vaccinia are available only for research purposes, but are undergoing
multicenter validation studies that might enable FDA to approve the test reagents for diag-
nostic use. 
Prophylaxis for Those at High Risk
Prophylactic treatment with VIG is not recommended for persons or close contacts with
contraindications to smallpox vaccination who are inadvertently inoculated or exposed.
Reporting adverse events
Suspected cases of these illnesses or other severe adverse events after smallpox vacci-
nation should be reported immediately to state health departments and to the Vaccine
Adverse Event Reporting System. Reports can be made online at https://secure.vaers.org/
VaersDataEntryintro.htm. To request clinical consultation and IND therapies for vaccinia-
related adverse reactions for civilians, contact your state health department or the CDC's
Clinician Information Line (877-554-4625). Those with suspected adverse events should
be removed from work until evaluated and cleared to return.  
Timing of Tuberculosis Screening and Smallpox Vaccination
Suppression of tuberculin skin test (TST) reactivity has been demonstrated after adminis-
tration of smallpox vaccine. Health care workers scheduled to receive an annual TST
should not receive the skin test for one month after smallpox vaccination to prevent pos-
sible false-negative reactions.
*DISCLOSURES:  Nothing to disclose.
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the dying patient, or the family member may
have victimized the patient. Staff must antici-
pate and be prepared to mediate in these
often-painful confrontations. 
Bereavement Support
Working continuously with terminally ill
patients can take an emotional toll on both staff
and volunteers, so it is important to have an
organized program to address their emotional
needs. Memorial services - ideally open to
both staff and inmates - should be held for
those who have died. 
Conclusion
The over two million individuals in this coun-
try's prisons and jails represent an aging pop-
ulation with multiple chronic medical problems.
Many prisoners are destined to die while incar-
cerated. Correctional systems have a respon-
sibility to attend to end of life issues, which
include advance directives and management
of pain and other symptoms of terminal condi-
tions. Although many jails and prisons choose
to transfer patients to community facilities for
end of life care, patients can be cared for in the
correctional setting in a secure, competen ,
compassionate manner. Close cooperation
between custody and medical staff is neces-
sary for the success of any correctional end of
life care program. With the active participation
of all those involved, terminally ill prisoners
who will not be released can be provided a
humane end of life experience within the cor-
rectional setting.
*DISCLOSURES: Nothing to disclose
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Providing Palliative Care...
(continued from page 5)
8th Northeast Correctional
Health Care Conference
May 21, 2003
Sturbridge, Massachusetts
On-site registration: $90
Call: 781-890-3435
Email: chcc@icg-ps.com
Legal Issues in Correctional
Health Care
Sponsored by NCCHC and the
American Bar Association Criminal
Justice Section
June 27-28, 2003
Chicago, Illinois
Call: 773-880-1460
Visit: http://www.ncchc.org/
edu_legal2003/legal_conf.pdf
American Correctional
Association Summer
Conference
August 9-13, 2003
Nashville, Tennessee
Call: 800-222-5646, ext. 1922
Visit: http://www.aca.org/conven-
tions/conventions_2003
_summer.htm
3rd Annual Intensive Review in
Correctional Medicine
Sponsored by the Correctional
Medicine Institute (CMI), 
the Society for Correctional
Physicians (SCP), and 
Johns Hopkins University
September 4-6, 2003
Baltimore, Maryland
Baltimore Marriott Waterfront Hotel
Call: 314-607-1565
Email: admin@cm-institute.org
Visit: http://www.cm-institute.org/
43rd Interscience Conference
on Antimicrobial Agents and
Chemotherapy (ICAAC)
September 14-17, 2003
Chicago, Illinois
Call: 202-737-3600
Email: icaac@asmusa.org
Visit: www.icaac.org/ICAAC.asp
The United States 
Conference on AIDS
Sponsored by the National
Minority AIDS Council
September 18-21, 2003
New Orleans, Louisiana
Call: 202-483-6622
Visit: www.nmac.org
National Conference on
Correctional Health Care 
October 4-8, 2003
Austin, Texas
Call: 773-880-1460
Visit: www.ncchc.org
Save the 
Dates
9
Report: U.S. Prison Population Tops 2 Million
The number of inmates in U.S. prisons and jails
rose to 2,019,234 last year, the first time the num-
ber has exceeded 2 million, according to a report
released by the Justice Department. California,
Texas, Florida and New York remain the four
largest state prison systems, though the number of
inmates in federal prisons for the first time sur-
passed that of any state, with nearly 162,000 fed-
eral inmates. The report also noted a 5.4%
increase in the number of people confined to local
and county jails, the largest growth in the jail pop-
ulation in five years. Other findings: about 12% of
all black men in the U.S. between 20-39 years old
were in prison or jail, compared to 4% of Hispanic
males and 1.6% of white males. New York Times
and Associated Press, 4/7/03
HIV
Study: Ending Segregation of HIV-Positive
Inmates Could Save Money
Alabama¹s prison system could save between
$306,000 and $392,000 per year if it didn¹t segre-
gate HIV-positive inmates from the rest of the
prison population, according to a report by the
Alabama Prison Project and the ACLU National
Prison Project. If the segregation ceased, 56
inmates would be eligible to join community-run
corrections programs. Community corrections pro-
grams cost the state $11 per day per inmate - $15
less per day than it costs for an inmate to remain
in prison. Alabama is the only state prison system
that still segregates HIV-positive prisoners.
Associated Press, 4/30/03
New Formulation of Viracept Approved by the
FDA
The FDA approved a new formulation of Viracept
(nelfinavir) that reduces the number of pills
patients must take each day. Previously available
in 50 mg oral powder and 250 mg tablets, Viracept
is now available in a 625 mg pill, reducing the num-
ber of tablets taken each day from 10 per day to
four per day. The 625mg tablets will be available in
the 3rd quarter of 2003 and will be parity priced
with the 250mg tablets. Viracept 250mg will be
continued to be manufactured. FDA Release,
4/30/03
CDC Urges Expanded HIV Screening,
Recommends Testing All Pregnant Women
The Centers for Disease Control and Prevention
(CDC), in partnership with other federal agencies,
is launching a new initiative to advance HIV pre-
vention activities. While previous CDC efforts have
focused mainly on preventing people from acquir-
ing HIV/AIDS, new strategies will focus on preven-
tion efforts for individuals already infected with HIV.
This includes increased efforts to diagnose people
who are not aware they are infected, and to edu-
cate each HIV-infected person on ways to prevent
spreading the disease. As part of the new initiative,
the CDC is recommending that HIV testing
become a routine part of medical care, and in par-
ticular, offered to all pregnant women. It also aims
to streamline the testing procedures so that pre-
vention counseling is not a prerequisite for testing.
The agency will be conducting demonstration pro-
jects in high-prevalence settings (including correc-
tional facilities) using the OraQuick HIV rapid test,
which provides results in 20 minutes. The full
report is available at www.cdc.gov/mmwr/preview/
mmwrhtml/mm5215a1.htm.CDC, 4/18/03
FDA Approves Valacyclovir for HIV-infected
Patients
GlaxoSmithKline announced that it has received
supplemental approval from the U.S. Food and
Drug Administration (FDA) to market its antiviral
valacyclovir HCl (Valtrex) as the first FDA-
approved antiviral therapy for the suppression of
recurrent genital herpes in HIV-infected individu-
als. Valtrex was already approved for the treatment
of herpes zoster and cold sores. Reuters, 4/3/03
Roche Gets FDA OK for Improved HIV Test
Roche announced that it has received FDA
approval for an automated version of a test used to
detect and measure viral levels in the blood of HIV-
positive patients. The Cobas Amplicor HIV-1
Monitor Test (version 1.5) can measure viral load
levels as low as 50 copies of HIV RNA per mil-
limeter of blood plasma. The test can also detect a
broader range of HIV-1 subtypes than previous
tests, according to Roche. Reuters, 4/11/03
Study: Physician Experience a Major
Contributor to AIDS Survival
Results from a study in Vancouver show that physi-
cian experience has an independent effect on the
survival of patients with AIDS. Investigators from
the British Columbia Centre for Excellence in
HIV/AIDS evaluated the impact of "non-immune-
based factors" in survival in 1400 HIV-infected
patients starting HAART for the first time, following
the cohort for 42 months. When HAART was initi-
ated at CD4 levels about 200, patients treated by
either experienced or inexperienced physicians
had similar survival rates. However, in patients with
CD4 counts <50, the hazard of death was greater
for patients treated by inexperienced physicians.
The study is presented in the March 28 issue of
AIDS.  Reuters, 4/14/03
TB
Am J Prev Med: Treatment for Latent TB in
Correctional Facilities
A field study conducted by the CDC in nearly 50
correctional facilities evaluated high-risk popula-
tions at risk for co-infection with tuberculosis (TB)
and HIV to find out if treating latent TB infection
(LTBI) in inmates was feasible. In 49 correctional
facilities in 12 states, 198,102 inmates had a tuber-
culin skin test (TST) read; 17% were positive. Of
those who had a known HIV test result, 14.5% test-
ed positive for HIV infection. Inmates with a posi-
tive TST were 4.2 times more likely than those with
a negative TST to be infected with HIV. HIV-posi-
tive patients who began the 12-month TB treat-
ment regimen were less likely than HIV-negative
patients (40% vs 68%, respectively) to complete
treatment. The results from the 8-year HIV-Related
TB Prevention (HRTP) were published in the April
2003 American Journal of Preventative Medicine.
Am J Prev Med 2003;24(3)
Inside News
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through November 30, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. For the first time, the number of people incarcerated in U.S.
prisons and jails has reached:
(a) 1.5 million
(b) 1.7 million
(c) 2.1 million
(d) 2.5 million
2. Neuropathic pain occurs when nerve endings are stimulated,
such as when a tumor expands in an organ or metastasizes to
bone, and is usually responsive to analgesics alone. 
(a) True
(b) False
3. Analgesics prescribed for severe pain for a terminally ill patient
should be administered: 
(a) Only at fixed intervals
(b) Only when the patient asks for them
(c) At fixed intervals, with "rescue" doses as needed
(d) None of the above
4. For terminally ill patients receiving palliative end- of- life care,
the maximum allowable dose of morphine is:
(a) 100 milligrams per day
(b) 250 milligrams per day
(c) 500 milligrams per day
(d) The amount necessary to relieve the patient's pain
5. Patients receiving narcotics should also routinely be pre-
scribed:
(a) Laxatives
(b) Antihistamines
(c) Anticonvulsants
(d) Antidepressants
6. In a correctional end -of- life care program, an appropriate
activity for inmate volunteers is:
(a) Dispensing medications
(b) Taking vital signs
(c) Reading to patients
(d) Bathing patients
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
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Brown Medical School.
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register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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